Lymphoma
≈ 11 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Lymphoma is a group of blood and lymph tumors that develop from lymphocytes (a type of white blood cell). The name typically refers to just the cancerous versions rather than all such tumors. Signs and symptoms may include enlarged lymph nodes, fever, drenching sweats, unintended weight loss, itching, and constantly feeling tired. The enlarged lymph nodes are usually painless. The sweats are most common at night. The two main categories of lymphomas are the non-Hodgkin lymphoma (NHL) (90% of cases) and Hodgkin lymphoma (HL) (10%). Lymphomas, leukemias and myelomas are a part of the broader group of tumors of the hematopoietic and lymphoid tissues. Risk factors for Hodgkin lymphoma include infection with Epstein–Barr virus and a history of the disease in the family. Risk factors for common types of non-Hodgkin lymphomas include autoimmune diseases, HIV/AIDS, infection with human T-lymphotropic virus, immunosuppressant medications, and some pesticides. Eating large amounts of red meat and tobacco smoking may also increase the risk. Diagnosis, if enlarged lymph nodes are present, is usually by lymph node biopsy. Blood, urine, and bone marrow testing may also be useful in the diagnosis. Medical imaging may then be done to determine if and where the cancer has spread. Lymphoma most often spreads to the lungs, liver, and brain.…
Lymphoma is a group of blood and lymph tumors that develop from lymphocytes (a type of white blood cell). The name typically refers to just the cancerous versions rather than all such tumors. Signs and symptoms may include enlarged lymph nodes, fever, drenching sweats, unintended weight loss, itching, and constantly feeling tired. The enlarged lymph nodes are usually painless. The sweats are most common at night. The two main categories of lymphomas are the non-Hodgkin lymphoma (NHL) (90% of cases) and Hodgkin lymphoma (HL) (10%). Lymphomas, leukemias and myelomas are a part of the broader group of tumors of the hematopoietic and lymphoid tissues. Risk factors for Hodgkin lymphoma include infection with Epstein–Barr virus and a history of the disease in the family. Risk factors for common types of non-Hodgkin lymphomas include autoimmune diseases, HIV/AIDS, infection with human T-lymphotropic virus, immunosuppressant medications, and some pesticides. Eating large amounts of red meat and tobacco smoking may also increase the risk. Diagnosis, if enlarged lymph nodes are present, is usually by lymph node biopsy. Blood, urine, and bone marrow testing may also be useful in the diagnosis. Medical imaging may then be done to determine if and where the cancer has spread. Lymphoma most often spreads to the lungs, liver, and brain. Treatment may involve one or more of the following: chemotherapy, radiation therapy, proton therapy, targeted therapy, and surgery. In some non-Hodgkin lymphomas, an increased amount of protein produced by the lymphoma cells causes the blood to become so thick that plasmapheresis is performed to remove the protein. Watchful waiting may be appropriate for certain types. The outcome depends on the subtype, with some being curable and treatment prolonging survival in most. The five-year survival rate in the United States for all Hodgkin lymphoma subtypes is 89%, while that for non-Hodgkin lymphomas is 74%. Worldwide, lymphomas developed in 566,000 people in 2012 and caused 305,000 deaths. They make up 3–4% of all cancers, making them as a group the seventh-most-common form. In children, they are the third-most-common cancer. They occur more often in the developed world than in the developing world.
Signs and symptoms
Lymphoma commonly presents with painless, persistent lymphadenopathy (swelling of the lymph nodes) and can vary from rapidly enlarging lymph nodes in aggressive lymphomas to fluctuating lymphadenopathy in slow-growing subtypes. B symptoms are a set of symptoms consisting of fever, night sweats, and unintended weight loss associated with Hodgkin and non-Hodgkin lymphomas. Patients with more advanced stages of lymphoma are more likely to be affected by these symptoms. The presence of lymphoma outside the lymph nodes can cause a variety of symptoms depending on the affected organ. Extranodal involvement is common in non-Hodgkin lymphoma, with 40% of patients experiencing some form of it. Aggressive non-Hodgkin lymphomas make systemic symptoms more likely. Mediastinal lymphadenopathy, and less commonly, pulmonary lymphoma, may cause cough, dyspnea, chest pain, or superior vena cava syndrome, due to compression of the windpipe, the superior vena cava, or nerves in the chest. Lymphoma in bone marrow can cause anemia, thrombocytopenia, and fatigue. Bone marrow involvement is most common in low-grade, non-Hodgkin lymphomas, and especially in follicular, mantle cell, and small B-cell lymphomas (40-90% of cases depending on subtype). Chronic pain, fullness, early satiety, and gastrointestinal bleeding are symptoms associated with gastrointestinal lymphoma. The gastrointestinal tract is the most common location for extranodal involvement with non-Hodgkin lymphomas, accounting for 30-40% of extranodal lymphomas in general, while in Hodgkin lymphomas, it is rare, accounting for less than 1% of cases. Although uncommon, involvement with the central nervous system can cause symptoms including confusion, double vision, headaches, nausea, and hearing loss. It is rare in Hodgkin lymphomas, with only 0.2% to 0.5% of patients experiencing it, but occurs more often in non-Hodgkin lymphoma, ranging from 2.8% in indolent forms to 24.4% in high-grade lymphoblastic and Burkitt lymphoma. Paraneoplastic syndromes are rare in lymphoma. Paraneoplastic cerebellar degeneration is most strongly associated with Hodgkin lymphomas, while polymyositis and dermatomyositis are associated with both Hodgkin and non-Hodgkin lymphomas.
Diagnosis
) for evaluation under light microscopy. Lymphoma is definitively diagnosed by a lymph-node biopsy or biopsy of extranodal tissue, which is examined under the microscope. This examination reveals histopathological features that may indicate lymphoma. Imaging may be performed as part of the initial workup for lymphoma. CT scans can identify enlarged lymph nodes, while fluorodeoxyglucose (FDG) PET imaging identifies areas of increased lymph node activity. Laboratory tests may also be used as part of initial workup to assess affected organ function, blood counts, and conditions that may affect treatment. Complete blood counts can show signs of bone marrow, spleen, and GI tract involvement through blood count abnormalities, including anemia, both low and high platelet count, and low white cell count. Testing for HIV and hepatitis B and C may also be performed due HIV being associated with an increased risk for lymphoma and hepatitis potentially reactivating with certain antibody treatments. After lymphoma is diagnosed, a variety of tests may be carried out to look for specific features characteristic of different types of lymphoma including immunophenotyping (targeting of proteins expressed on cells), flow cytometry, and fluorescence in situ hybridization testing. Lymphoma subtypes (WHO 2008) B-cell chronic lymphocytic leukemia/small cell lymphoma 3–4% of lymphomas in adults Small resting lymphocytes mixed with variable numbers of large activated cells, lymph nodes diffusely effaced CD5, surface immunoglobulin 5-year survival rate 50%. Occurs in older adults, usually involves lymph nodes, bone marrow, and spleen; most patients have peripheral blood involvement, indolent B-cell prolymphocytic leukemia Lymphoplasmacytic lymphoma (such as Waldenström macroglobulinemia) Splenic marginal zone lymphoma Hairy cell leukemia Plasma cell neoplasms: Plasma cell myeloma (also known as multiple myeloma) Plasmacytoma Monoclonal immunoglobulin deposition diseases Heavy chain diseases Extranodal marginal zone B cell lymphoma, also called MALT lymphoma About 5% of lymphomas in adults Variable cell size and differentiation, 40% show plasma cell differentiation, homing of B cells to epithelium creates lymphoepithelial lesions. CD5, CD10, surface Ig Frequently occurs outside lymph nodes, very indolent, may be cured by local excision Nodal marginal zone B cell lymphoma Follicular lymphoma About 40% of lymphomas in adults Small "cleaved" [cleft] cells (centrocytes) mixed with large activated cells (centroblasts), usually nodular ("follicular") growth pattern CD10, surface Ig About 72–77% Occurs in older adults, usually involves lymph nodes, bone marrow, and spleen, associated with t(14;18) translocation overexpressing Bcl-2, indolent Primary cutaneous follicle center lymphoma Mantle cell lymphoma About 3–4% of lymphomas in adults Lymphocytes of small to intermediate size growing in a diffuse pattern CD5 About 50 to 70% Occurs mainly in adult males, usually involves lymph nodes, bone marrow, spleen, and GI tract, associated with t(11;14) translocation overexpressing cyclin D1, moderately aggressive Diffuse large B-cell lymphoma, not otherwise specified About 40–50% of lymphomas in adults Variable, most resemble B cells of large germinal centers, diffuse growth pattern Variable expression of CD10 and surface Ig Five-year survival rate 60% Occurs in all ages, but most commonly in older adults, may occur outside lymph nodes, aggressive Diffuse large B-cell lymphoma associated with chronic inflammation Epstein–Barr virus positive diffuse large B-cell lymphoma, not otherwise specified Lymphomatoid granulomatosis Primary mediastinal (thymic) large B-cell lymphoma Intravascular large B-cell lymphoma ALK+ large B-cell lymphoma Plasmablastic lymphoma Primary effusion lymphoma Large B-cell lymphoma arising in HHV8-associated multicentric Castleman's disease Burkitt lymphoma/leukemia
Treatment
The treatment of lymphoma changes according to disease subtype, staging, anatomical distribution, and patient factors like age, symptoms, and performance status. For aggressive Hodgkin and non-Hodgkin lymphomas, treatment is often administered with the intent to cure, while treatment for slow-growing non-Hodgkin lymphomas involves more watchful waiting and symptom alleviation. Treatment may involve a combination of methods, including chemotherapy, radiation therapy, immunotherapy, targeted therapy, hematopoietic stem-cell transplants, or watchful waiting. Advancements in diagnostics have allowed more individual treatment based on lymphoma subtype and patient circumstances.
Prognosis
Epidemiology
Between 1990 and 2021, Lymphoma was the most common form of hematological malignancy, or "blood cancer", in the developed world. Taken together, lymphomas represent 5.3% of all cancers (excluding simple basal cell and squamous cell skin cancers) in the United States and 55.6% of all blood cancers. According to the U.S. National Institutes of Health, lymphomas account for about 5%, and Hodgkin lymphoma in particular accounts for less than 1% of all cases of cancer in the United States. Because the whole lymphatic system is part of the body's immune system, people with a weakened immune system, such as from HIV infection or certain drugs or medications, also have a higher number of cases of lymphoma.
History
Thomas Hodgkin published the first description of lymphoma in 18321, specifically of the form named after him. Since then, many 70 other types of lymphoma have been described based on the range of their activity.
Research
The two types of lymphoma research are clinical or translational research and basic research. Clinical/translational research focuses on studying the disease in a defined and generally immediately applicable way, such as testing a new drug in people. Studies may focus on effective means of treatment, better ways of treating the disease, improving the quality of life for people, or appropriate care in remission or after cures. Hundreds of clinical trials are being planned or conducted at any given time. Basic science research studies the disease process at a distance, such as seeing whether a suspected carcinogen can cause healthy cells to turn into lymphoma cells in the laboratory or how the DNA changes inside lymphoma cells as the disease progresses. The results from basic research studies are generally less immediately useful to people with the disease, but can improve scientists' understanding of lymphoma and form the foundation for future, more effective treatments.
Other animals
Text derived from https://en.wikipedia.org/w/index.php?oldid=1377516969 under CC BY-SA 4.0; modifications have been made.
References
- ↩Wikipedia “Lymphoma” publication date (×1) · confidence 0.95 revision URL